222. Primary nephrotic syndrome
234 clinical trials,   241 drugs   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02399462
(ClinicalTrials.gov)
November 20208/1/2015Acthar for Treatment of Post-transplant FSGSActhar for Treatment of Post-transplant FSGSFSGS;Renal Transplantation;Kidney TransplantationDrug: ActharUniversity of North Carolina, Chapel HillMallinckrodtNot yet recruiting18 YearsN/AAll20Phase 4United States
2NCT02683889
(ClinicalTrials.gov)
February 1, 20195/2/2016Use of Acthar in Patients With FSGS That Will be Undergoing Renal TransplantationThe Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal TransplantFSGSDrug: ActharUniversity of Colorado, DenverNULLRecruiting18 Years80 YearsAll20Phase 3United States
3NCT03025828
(ClinicalTrials.gov)
March 19, 201817/1/2017Adrenocorticotropic Hormone in Membranous NephropathyChanges in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous NephropathyMembranous NephropathyDrug: ACTHarIcahn School of Medicine at Mount SinaiNULLRecruiting18 Years70 YearsAll25Phase 4United States
4NCT02633046
(ClinicalTrials.gov)
May 16, 201615/12/2015Acthar for Treatment-Resistant or Treatment-Intolerant ProteinuriaTreatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)Idiopathic Focal Segmental GlomerulosclerosisDrug: Acthar GelMallinckrodt ARD LLCNULLCompleted18 YearsN/AAll64Phase 4United States;Argentina;Australia;Chile;Mexico;Peru;Turkey;Canada;Hong Kong;New Zealand;Puerto Rico
5NCT01386554
(ClinicalTrials.gov)
August 201129/6/2011Acthar for Treatment of Proteinuria in Membranous Nephropathy PatientsA Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)Proteinuria;Idiopathic Membranous NephropathyDrug: Repository Corticotropin Injection;Drug: PlaceboMallinckrodtNULLCompleted18 YearsN/AAll60Phase 4United States;Canada;Chile;Mexico;Turkey
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01155141
(ClinicalTrials.gov)
September 200929/6/2010Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTHIdiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTHKidney DiseasesDrug: H.P. Acthar GelStanford UniversityMallinckrodtCompleted16 Years65 YearsAll15Phase 4United States